Mutation News and Research

RSS

Research reveals gene activation is linked to most aggressive type of brain cancer

Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.

18 Jan 2010

HHMI: Distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors

According to modern biology textbooks, a single genetic mutation is rarely enough to cause cancer. It is generally thought that cells must accumulate a series of mutations that work together to trigger tumor development.

18 Jan 2010

Findings could pave way for new therapeutic approaches for Friedreich's ataxia

Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI).

18 Jan 2010

Scientists discover new links between inherited blindness and AHI1 gene

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine have discovered new links between a common form of inherited blindness affecting children and a gene known as Abelson helper integration site-1 (AHI1).

18 Jan 2010

New genetic evidence can improve avian influenza surveillance programs

Genetic analyses of avian influenza in wild birds can help pinpoint likely carrier species and geographic hot spots where Eurasian viruses would be most likely to enter North America, according to new U.S. Geological Survey research.

13 Jan 2010

Growth hormone deficiency can lead to memory deficits later in life

Scientists have shown that early growth hormone supplementation in rats with growth hormone deficiency can prevent defects in memory developing later in adulthood. The study, published in the Journal of Endocrinology is the first to show that memory defects in adults as a result of growth hormone deficiency arising in childhood can be prevented by growth hormone treatment during adolescence.

13 Jan 2010

Researchers discover 93-gene signature associated with EGFR mutations in lung cancer tumors

Epidermal growth factor receptor (EGFR) is a validated therapeutic target for non-small cell lung cancer. Researchers have now discovered a 93-gene signature that is associated with the presence of EGFR mutations in tumors from lung cancer patients and is a favorable prognostic marker in patients with early stage lung cancer.

13 Jan 2010

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Brain cancer is the leading cause of cancer death in children. Now a more accurate diagnosis of childhood brain cancers may soon be possible, according to researchers at Huntsman Cancer Institute (HCI) at the University of Utah. The information is published online today in the journal Cancer Research.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

12 Jan 2010

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference.

12 Jan 2010

New findings would allow doctors to tailor drug cocktails for particular viral strains

Chemists at UC San Diego and statisticians at Harvard University have developed a novel way to trace mutations in HIV that lead to drug resistance. Their findings, once expanded to the full range of drugs available to treat the infection, would allow doctors to tailor drug cocktails to the particular strains of the virus found in individual patients.

12 Jan 2010

Protein bits produced by unusual "reading" of HIV genome can induce immune responses

Two new studies showing that protein bits produced by unusual "reading" of the HIV genome can induce immune responses will appear online in the Journal of Experimental Medicine on Jan. 11 (www.jem.org).

12 Jan 2010

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

12 Jan 2010

Cancer drug may provide an effective secondary treatment for gut tumor

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research.

12 Jan 2010

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in the Phase 1 clinical study of BMN 195, a small molecule utrophin upregulator, for the treatment of Duchenne muscular dystrohpy (DMD). Initial top-line results are expected in the third quarter of 2010.

12 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Researchers identify treatment to reduce health problems associated with enzyme defect

An experimental compound repaired a defective alcohol metabolism enzyme that affects an estimated 1 billion people worldwide, according to research supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

10 Jan 2010

Autism spectrum disorders result from miswiring of connections in developing brain

Studying a rare disorder known as tuberous sclerosis complex (TSC), researchers at Children's Hospital Boston add to a growing body of evidence suggesting that autism spectrum disorders, which affect 25 to 50 percent of TSC patients, result from a miswiring of connections in the developing brain, leading to improper information flow.

10 Jan 2010

Mutation News and Research

Research reveals gene activation is linked to most aggressive type of brain cancer

HHMI: Distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors

Findings could pave way for new therapeutic approaches for Friedreich's ataxia

Scientists discover new links between inherited blindness and AHI1 gene

New genetic evidence can improve avian influenza surveillance programs

Growth hormone deficiency can lead to memory deficits later in life

Researchers discover 93-gene signature associated with EGFR mutations in lung cancer tumors

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

New findings would allow doctors to tailor drug cocktails for particular viral strains

Protein bits produced by unusual "reading" of HIV genome can induce immune responses

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

Cancer drug may provide an effective secondary treatment for gut tumor

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Researchers identify treatment to reduce health problems associated with enzyme defect

Autism spectrum disorders result from miswiring of connections in developing brain

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News